An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

Marco Montillo; Ian Flinn; Matthew Davids; Peter Hillmen; Julio Delgado; Bryone Kuss; Constantine Tam; Ulrich Jager; Paolo Ghia; Stephan Stilgenbauer; Stephanie Lustgarten; David T. Weaver; Hagop Youssoufian; Florence Cymbalista

doi:10.1080/10428194.2020.1732667

An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

Marco Montillo, Ian Flinn, Matthew Davids, Peter Hillmen, Julio Delgado, Bryone Kuss, Constantine Tam, Ulrich Jager, Paolo Ghia, Stephan Stilgenbauer, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Florence Cymbalista

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacy
and safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).

Original language	English
Pages (from-to)	116-117
Number of pages	2
Journal	Leukemia and Lymphoma
Volume	61
Issue number	S1
DOIs	https://doi.org/10.1080/10428194.2020.1732667
Publication status	Published - 21 May 2020
Event	XVIII International Workshop on Chronic Lymphocytic Leukemia - EICC: Edinburgh International Conference Centre, Edinburgh, United Kingdom Duration: 20 Sept 2019 → 23 Sept 2019 https://www.iwcll2019.org/ (Conference website)

Keywords

Duvelisib
chronic lymphocytic leukemia
small lymphocytic lymphoma
Prior therapy
inhibitor
relapse prevention

Access to Document

10.1080/10428194.2020.1732667Licence: In Copyright

Cite this

Montillo, M., Flinn, I., Davids, M., Hillmen, P., Delgado, J., Kuss, B., Tam, C., Jager, U., Ghia, P., Stilgenbauer, S., Lustgarten, S., Weaver, D. T., Youssoufian, H., & Cymbalista, F. (2020). An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies. Leukemia and Lymphoma, 61(S1), 116-117. https://doi.org/10.1080/10428194.2020.1732667

@article{16d03d4fada644f5ac6d2647e01154ee,

title = "An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies",

abstract = "Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacyand safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).",

keywords = "Duvelisib, chronic lymphocytic leukemia, small lymphocytic lymphoma, Prior therapy, inhibitor, relapse prevention",

author = "Marco Montillo and Ian Flinn and Matthew Davids and Peter Hillmen and Julio Delgado and Bryone Kuss and Constantine Tam and Ulrich Jager and Paolo Ghia and Stephan Stilgenbauer and Stephanie Lustgarten and Weaver, {David T.} and Hagop Youssoufian and Florence Cymbalista",

year = "2020",

month = may,

day = "21",

doi = "10.1080/10428194.2020.1732667",

language = "English",

volume = "61",

pages = "116--117",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "S1",

note = "XVIII International Workshop on Chronic Lymphocytic Leukemia, XVIII iwCLL ; Conference date: 20-09-2019 Through 23-09-2019",

url = "https://www.iwcll2019.org/",

}

Montillo, M, Flinn, I, Davids, M, Hillmen, P, Delgado, J, Kuss, B, Tam, C, Jager, U, Ghia, P, Stilgenbauer, S, Lustgarten, S, Weaver, DT, Youssoufian, H & Cymbalista, F 2020, 'An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies', Leukemia and Lymphoma, vol. 61, no. S1, pp. 116-117. https://doi.org/10.1080/10428194.2020.1732667

TY - JOUR

T1 - An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

AU - Montillo, Marco

AU - Flinn, Ian

AU - Davids, Matthew

AU - Hillmen, Peter

AU - Delgado, Julio

AU - Kuss, Bryone

AU - Tam, Constantine

AU - Jager, Ulrich

AU - Ghia, Paolo

AU - Stilgenbauer, Stephan

AU - Lustgarten, Stephanie

AU - Weaver, David T.

AU - Youssoufian, Hagop

AU - Cymbalista, Florence

PY - 2020/5/21

Y1 - 2020/5/21

N2 - Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacyand safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).

AB - Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacyand safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).

KW - Duvelisib

KW - chronic lymphocytic leukemia

KW - small lymphocytic lymphoma

KW - Prior therapy

KW - inhibitor

KW - relapse prevention

UR - http://www.scopus.com/inward/record.url?scp=85085158250&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1732667

DO - 10.1080/10428194.2020.1732667

M3 - Meeting Abstract

SN - 1042-8194

VL - 61

SP - 116

EP - 117

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - S1

T2 - XVIII International Workshop on Chronic Lymphocytic Leukemia

Y2 - 20 September 2019 through 23 September 2019

ER -

An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this